Vaccine preventable zoonotic diseases: challenges and opportunities for public health progress

A Carpenter, MA Waltenburg, A Hall, J Kile, M Killerby… - Vaccines, 2022 - mdpi.com
Zoonotic diseases represent a heavy global burden, causing important economic losses,
impacting animal health and production, and costing millions of human lives. The …

Current leishmaniasis drug discovery

AC Pinheiro, MVN de Souza - RSC Medicinal Chemistry, 2022 - pubs.rsc.org
Leishmaniasis is a complex protozoan infectious disease and, associated with malnutrition,
poor health services and unavailability of prophylactic control measures, neglected …

[HTML][HTML] Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis–A review

P Prasanna, P Kumar, S Kumar, VK Rajana… - Biomedicine & …, 2021 - Elsevier
The study of tropical diseases like leishmaniasis, a parasitic disease, has not received much
attention even though it is the second-largest infectious disease after malaria. As per the …

Determinants of innate immunity in visceral leishmaniasis and their implication in vaccine development

G Volpedo, T Pacheco-Fernandez… - Frontiers in …, 2021 - frontiersin.org
Leishmaniasis is endemic to the tropical and subtropical regions of the world and is
transmitted by the bite of an infected sand fly. The multifaceted interactions between …

A recombinant chimeric protein-based vaccine containing T-cell epitopes from amastigote proteins and combined with distinct adjuvants, induces immunogenicity and …

DP Lage, DL Vale, FP Linhares, CS Freitas… - Vaccines, 2022 - mdpi.com
Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL),
a potentially fatal disease caused by infection with Leishmania parasites. In the current …

Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis

M de Carvalho Clímaco, LA de Figueiredo, RC Lucas… - Vaccine, 2023 - Elsevier
Leishmania spp. and Trypanosoma cruzi are parasitic kinetoplastids of great medical and
epidemiological importance since they are responsible for thousands of deaths and …

Road‐map of pre‐clinical treatment for Visceral Leishmaniasis

P Mazire, V Agarwal, A Roy - Drug Development Research, 2022 - Wiley Online Library
Visceral leishmaniasis (VL) or Kala‐azar, is the most lethal form of leishmaniasis, is still
prevalent in many countries where it is endemic. It is a threat to human life caused by …

New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine

DS Oliveira, MF Zaldívar, AAM Gonçalves, LA Resende… - Vaccines, 2024 - mdpi.com
The development of prophylactic vaccines is important in preventing and controlling
diseases such as visceral leishmaniasis (VL), in addition to being an economic measure for …

Intramuscular Immunization with a Liposomal Multi-Epitope Chimeric Protein Induces Strong Cellular Immune Responses against Visceral Leishmaniasis

M Agallou, M Margaroni, E Karagouni - Vaccines, 2023 - mdpi.com
Control of the intracellular parasite Leishmania (L.) requires the activation of strong type 1
cellular immune responses. Towards this goal, in the present study, a multiepitope chimeric …

rMELEISH: a novel recombinant multiepitope-based protein applied to the serodiagnosis of both canine and human visceral leishmaniasis

DS Dias, JM Machado, PAF Ribeiro, AS Machado… - Pathogens, 2023 - mdpi.com
Background: visceral leishmaniasis (VL) is a critical public health problem in over ninety
countries. The control measures adopted in Brazil have been insufficient when it comes to …